Dechra Pharmaceuticals (LON:DPH) Receives “Buy” Rating from Numis Securities

Numis Securities restated their buy rating on shares of Dechra Pharmaceuticals (LON:DPH – Get Rating) in a report published on Monday, Digital Look reports. The brokerage currently has a GBX 4,000 ($49.75) price objective on the stock.

DPH has been the topic of a number of other research reports. Jefferies Financial Group reissued a buy rating and set a GBX 3,112 ($38.71) price target on shares of Dechra Pharmaceuticals in a research report on Tuesday, February 28th. Berenberg Bank reaffirmed a hold rating and issued a GBX 2,850 ($35.45) target price on shares of Dechra Pharmaceuticals in a report on Monday, February 27th. Finally, JPMorgan Chase & Co. reduced their target price on Dechra Pharmaceuticals from GBX 4,600 ($57.21) to GBX 4,000 ($49.75) and set an overweight rating on the stock in a report on Tuesday, March 7th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Dechra Pharmaceuticals currently has an average rating of Moderate Buy and a consensus target price of GBX 3,592.40 ($44.68).

Dechra Pharmaceuticals Trading Down 13.0 %

Shares of LON:DPH opened at GBX 3,174 ($39.48) on Monday. The company has a market capitalization of £3.61 billion, a P/E ratio of 8,816.67, a P/E/G ratio of 1.42 and a beta of 0.76. Dechra Pharmaceuticals has a 1 year low of GBX 2,473.32 ($30.76) and a 1 year high of GBX 3,882 ($48.28). The company has a debt-to-equity ratio of 60.73, a current ratio of 2.73 and a quick ratio of 1.66. The business’s 50 day simple moving average is GBX 3,198.02 and its 200 day simple moving average is GBX 2,939.06.

Dechra Pharmaceuticals Cuts Dividend

The company also recently disclosed a dividend, which was paid on Thursday, April 13th. Investors of record on Thursday, March 9th were issued a dividend of GBX 12.50 ($0.16) per share. This represents a dividend yield of 0.4%. The ex-dividend date was Thursday, March 9th. Dechra Pharmaceuticals’s dividend payout ratio (DPR) is 12,500.00%.

About Dechra Pharmaceuticals

(Get Rating)

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.